Volume 14, no. 4
Pages 48-53

We aimed to evaluate and compare the capabilities of various diagnostic methods in detecting lung metastases of differentiated thyroid cancer (DTC). We retrospectively studied 36 patients (mean age 53 years, 33 females and 3 males) with metastases in lungs of DTC (29 papillary DTC and 7 follicular DTC), followed in the radiotherapy department of systemic therapy of State health care facility “Chelyabinsk Regional Clinical Oncology Dispensary” between 2011 and 2014. On chest radiography lung metastases were observed in 13 patients (36 %); in 23 patients (64 %) chest X-ray no revealed lesions in the lungs. Whole body scintigraphy with I-131 was informative in 24 patients (67 %) and did not reveal an increased accumulation of the radiopharmaceutical in the lungs of 12 patients (33 %).
Multi-slice spiral computed tomography (MSCT) of the chest was performed in 22 patients (61 %), of whom 21 patients (95 %) had lesions in the lungs from 1.4mm to 20 mm. PET / CT with 18-FDG was performed in 18 of 36 patients (50 %), which showed pathological lesions in the lungs from 3 mm to 26 mm in all 18 patients (100 %) of these 16 patients (88 %) metastatic lesions identified exclusively only with MSCT. Thus, the most sensitive methods in detecting lung metastases are MSCT (95 %), PET / CT with 18-FDG (100 % due to the existence of a regime MSCT) and whole-body scintigraphy with I-131 (67 %). For suspected lung metastases of DTC: 1) chest X-ray should be used as a screening method for the survey; 2) whole body scintigraphy with I-131 should be performed in all patients; 3) MSCT of the chest is the “gold standard” for diagnosis; 4) PET / CT with 18-FDG should not be used in routine practice.

Full text

Sources:

1. Kaprin A.D., Starinskiy V.V., Petrova G.V. Zlokachestvennye novoobrazovaniya v Rossii v 2012 g. (zabolevaemost' i smertnost') [Malignancies in Russia in 2012 (Morbidity and Mortality)]. Moscow, FGBI “MNIOI them. P.A. Herzen” Russian Ministry of Health Publ., 2014. 250 p.
2. Sherman S.I. Thyroid Carcinoma. Lancet, 2003, vol. 361, pp. 501–511.

3. Eustatia-Rutten C.F., Corssmit E.P., Biermasz N.R., Pereira A.M., Romijn J.A., Smit J.W. Survival and Death Causes in Differentiated Thyroid Carcinoma. The Journal of Clinical Endocrinology and Metabolism, 2006, vol. 91, no. 1, pp. 313–319.
4. Christine J., O’Neill, Oucharek J., Learoyd D., Sidhu S.B. O’Neill Standard and Emerging Therapies for Metastatic Differentiated Thyroid Cancer. The Oncologist, 2010, vol. 15, pp. 146–156.
5. Durante C., Haddy N., Baudin E. Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma. Benefits and Limits of Radioiodine Therapy. The Journal of Clinical Endocrinology and Metabolism, 2006, vol. 91, no. 8, pp. 2892–2289.
6. Dinneen S.F., Valimaki M.J., Bergstralh E.J. Distant Metastases in Papillary Thyroid Carcinoma: 100 Cases Observed at one Institution During 5 Decades. The Journal of Clinical Endocrinology and Metabolism, 1995, vol. 80, no. 7, pp. 2041–2045.
7. Valdina E.A. Zabolevaniya shchitovidnoy zhelezy. Rukovodstvo [Thyroid Disease. A Guide]. St. Peterburg, Peter Publ., 2006. 368 p.
8. Showalter T.N., Siegel B.A., Moley J.F. Prognostic Factors in Patients with Well-Differentiated Thyroid Cancer Presenting with Pulmonary Metastasis. Cancer Biotherapy and Radiopharmaceuticals, 2008, vol. 23, no. 5, pp. 655–659.
9. Sampson E., Brierley J.D., Le L.W. Clinical Management and Outcome of Papillary and Follicular (Differentiated) Thyroid Cancer Presenting with Distant Metastasis at Diagnosis. Cancer, 2007, vol. 110, no. 7, pp. 1451–1456.
10. Schlumberger M.J. Diagnostic Follow-Up of Well-Differentiated Thyroid Carcinoma: Historical Perspective and Current Status. The Journal of Endocrinological Investigation, 1999, vol. 22, no. 11, pp. 3–7.
11. Casara D., Rubello D., Saladini G. Different Features of Pulmonary Metastases in Differentiated Thyroid Cancer: Natural History and Multivariate Analysis of Prognostic Variables. The Journal of Nuclear Medicine, 1993, vol. 34, no. 11, pp. 1626–1631.
12. Schlumberger M.J., Arcangioli O., Piekarski J.D. Detection and Treatment of Lung Metastases of Differentiated Thyroid Carcinoma in Patients with Normal Chest X-Rays. The Journal of Nuclear Medicine, 1988, vol. 29, no. 11, pp. 1790–1794.
13. Wang H., Fu H.L., Li J.N. Comparison of Whole-Body 18F-FDG SPECT and Posttherapeutic I-131 Scintigraphy in the Detection of Metastatic Thyroid Cancer. Clinical Imaging, 2008, vol. 32, no 1, pp. 32–37.
14. Hooft L., Hoekstra O.S., Devillé W. Diagnostic Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Follow-Up of Papillary or Follicular Thyroid Cancer. The Journal of Clinical Endocrinology and Metabolism, 2001, vol. 86, no. 8, pp. 3779–3786.
15. Khan N., Oriuchi N., Higuchi T. PET in the Follow-Up of Differentiated Thyroid Cancer. British Journal of Radiology, 2003, vol. 76, no. 910, pp. 690–695.
16. Sisson J.C., Ackerman R.J., Meyer M.A. Uptake of 18-Fluoro-2-Deoxy-D-Glucose by Thyroid Cancer: Implications for Diagnosis and Therapy. The Journal of Clinical Endocrinology and Metabolism, 1993, vol. 77, no. 4, pp. 1090–1994.